Buy Or Sell Opportunity • Mar 03
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to €0.24. The fair value is estimated to be €0.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%. お知らせ • Feb 11
Neurone Studio S.A. to Report Q4, 2025 Results on Feb 13, 2026 Neurone Studio S.A. announced that they will report Q4, 2025 results on Feb 13, 2026 Buy Or Sell Opportunity • Jan 16
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at €0.25. The fair value is estimated to be €0.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%. Buy Or Sell Opportunity • Dec 31
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to €0.23. The fair value is estimated to be €0.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%. New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (€672.0k market cap, or US$781.2k). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Buy Or Sell Opportunity • Dec 08
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to €0.22. The fair value is estimated to be €0.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 165% over the last 3 years. Earnings per share has grown by 26%. お知らせ • Nov 11
Neurone Studio S.A. to Report Q3, 2025 Results on Nov 13, 2025 Neurone Studio S.A. announced that they will report Q3, 2025 results on Nov 13, 2025 New Risk • Sep 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (€909.9k market cap, or US$1.07m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding). New Risk • Sep 05
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł213k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł213k free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (€671.6k market cap, or US$789.4k). New Risk • Mar 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł324k free cash flow). Negative equity (-zł141k). Revenue is less than US$1m. Market cap is less than US$10m (€837.4k market cap, or US$868.5k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł324k free cash flow). Negative equity (-zł141k). Revenue is less than US$1m. Market cap is less than US$10m (€484.6k market cap, or US$507.7k). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). お知らせ • Jun 18
Neurone Studio S.A., Annual General Meeting, Jul 11, 2024 Neurone Studio S.A., Annual General Meeting, Jul 11, 2024. New Risk • Aug 25
New major risk - Negative shareholders equity The company has negative equity. Total equity: -zł6.8k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł329k free cash flow). Negative equity (-zł6.8k). Revenue is less than US$1m (zł250 revenue, or US$60.0). Market cap is less than US$10m (€982.7k market cap, or US$1.06m). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding). お知らせ • Jun 04
Neurone Studio S.A., Annual General Meeting, Jun 30, 2023 Neurone Studio S.A., Annual General Meeting, Jun 30, 2023, at 11:00 Central European Standard Time. お知らせ • Jun 08
Neurone Studio S.A., Annual General Meeting, Jun 30, 2022 Neurone Studio S.A., Annual General Meeting, Jun 30, 2022, at 13:00 Central European Standard Time. Is New 90 Day High Low • Feb 13
New 90-day low: €0.71 The company is down 22% from its price of €0.92 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is up 13% over the same period. Is New 90 Day High Low • Oct 26
New 90-day low: €0.85 The company is down 27% from its price of €1.17 on 28 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is up 20% over the same period. Is New 90 Day High Low • Sep 29
New 90-day low: €0.85 The company is down 14% from its price of €1.00 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Entertainment industry, which is up 8.0% over the same period.